Literature DB >> 33433585

Dose-response and functional role of whey permeate as a source of lactose and milk oligosaccharides on intestinal health and growth of nursery pigs.

K Jang1, J M Purvis2, S W Kim1.   

Abstract

Two experiments were conducted to evaluate dose-response and supplemental effects of whey permeate on growth performance and intestinal health of nursery pigs. In Exp. 1, 1,080 pigs weaned at 6.24 kg body weight (BW) were allotted to 5 treatments (8 pens/treatment) with increasing levels of whey permeate in 3 phases (from 10 to 30%, 3 to 23%, and 0 to 9% for phase 1, 2, and 3, respectively) fed until 11 kg BW and then fed a common phase 4 diet (0% whey permeate) until 25 kg BW in a 48 d feeding trial. Feed intake and BW were measured at the end of each phase. In Exp. 2, 1,200 nursery pigs at 7.50 kg BW were allotted to 6 treatments (10 pens/treatment) with increasing levels of whey permeate from 0 to 18.75% fed until 11 kg BW. Feed intake and BW were measured during 11 d. Six pigs per treatment (1 per pens) were euthanized to collect the jejunum to evaluate tumor necrosis factor alpha, interleukin-8 (IL-8), transforming growth factor beta 1, mucin 2, histomorphology, digestive enzyme activity, crypt cell proliferation rate, and jejunal mucosa-associated microbiota. Data were analyzed using contrasts in the MIXED procedure and a broken-line analysis using the NLIN procedure of SAS. In Exp. 1, increasing whey permeate had quadratic effect (P < 0.05) on feed efficiency (G:F; maximum: 1.35 at 18.3%) in phase 1. Increasing whey permeate linearly increased (P < 0.05) average daily gain (ADG; 292 to 327 g/d) and G:F (0.96 to 1.04) of pigs in phase 2. In Exp. 2, increasing whey permeate linearly increased (P < 0.05) ADG (349 to 414 g/d) and G:F (0.78 to 0.85), and linearly increased (P < 0.05) crypt cell proliferation rate (27.8 to 37.0%). The breakpoint from a broken-line analysis was obtained at 13.6% whey permeate for maximal G:F. Increasing whey permeate tended to change IL-8 (quadratic, P = 0.052; maximum: 223 pg/mg at 10.9%), to decrease Firmicutes:Bacteroidetes (P = 0.073, 1.59 to 1.13), increase (P = 0.089) Bifidobacteriaceae (0.73 to 1.11%), and to decrease Enterobacteriaceae (P = 0.091, 1.04 to 0.52%) and Stretococcaceae (P = 0.094, 1.50 to 0.71%) in the jejunal mucosa. In conclusion, dietary inclusion of whey permeate increased growth of nursery pigs from 7 to 11 kg BW. Pigs grew most efficiently with 13.6% whey permeate. Improvement in growth performance partly attributed from stimulating intestinal immune response and enterocyte proliferation with positive changes in jejunal mucosa-associated microbiota in nursery pigs.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society of Animal Science. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Keywords:  Growth performance; Intestinal health; Microbiome; Nursery pig; Whey permeate

Year:  2021        PMID: 33433585     DOI: 10.1093/jas/skab008

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  80 in total

1.  Bifidobacteria can protect from enteropathogenic infection through production of acetate.

Authors:  Shinji Fukuda; Hidehiro Toh; Koji Hase; Kenshiro Oshima; Yumiko Nakanishi; Kazutoshi Yoshimura; Toru Tobe; Julie M Clarke; David L Topping; Tohru Suzuki; Todd D Taylor; Kikuji Itoh; Jun Kikuchi; Hidetoshi Morita; Masahira Hattori; Hiroshi Ohno
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes.

Authors:  Zhuo-Teng Yu; Ceng Chen; David S Newburg
Journal:  Glycobiology       Date:  2013-09-07       Impact factor: 4.313

Review 3.  Breast milk oligosaccharides: structure-function relationships in the neonate.

Authors:  Jennifer T Smilowitz; Carlito B Lebrilla; David A Mills; J Bruce German; Samara L Freeman
Journal:  Annu Rev Nutr       Date:  2014-05-15       Impact factor: 11.848

4.  Bioactive Whey Protein Concentrate and Lactose Stimulate Gut Function in Formula-fed Preterm Pigs.

Authors:  Yanqi Li; Duc Ninh Nguyen; Karina Obelitz-Ryom; Anders D Andersen; Thomas Thymann; Dereck E W Chatterton; Stig Purup; Anne B Heckmann; Stine B Bering; Per T Sangild
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

5.  Dietary Human Milk Oligosaccharides but Not Prebiotic Oligosaccharides Increase Circulating Natural Killer Cell and Mesenteric Lymph Node Memory T Cell Populations in Noninfected and Rotavirus-Infected Neonatal Piglets.

Authors:  Sarah S Comstock; Min Li; Mei Wang; Marcia H Monaco; Theresa B Kuhlenschmidt; Mark S Kuhlenschmidt; Sharon M Donovan
Journal:  J Nutr       Date:  2017-05-10       Impact factor: 4.798

6.  Comparison of dried whey permeate and a carbohydrate product in diets for nursery pigs.

Authors:  V D Naranjo; T D Bidner; L L Southern
Journal:  J Anim Sci       Date:  2010-01-29       Impact factor: 3.159

7.  Effects of diet complexity and dietary lactose levels during three starter phases on postweaning pig performance.

Authors:  D C Mahan; N D Fastinger; J C Peters
Journal:  J Anim Sci       Date:  2004-09       Impact factor: 3.159

8.  Dietary bovine lactoferrin increases intestinal cell proliferation in neonatal piglets.

Authors:  Elizabeth A Reznikov; Sarah S Comstock; Cuiyi Yi; Nikhat Contractor; Sharon M Donovan
Journal:  J Nutr       Date:  2014-07-23       Impact factor: 4.798

9.  Testing the hypothesis that crypt cell hyperplasia inhibits lactase expression by mouse jejunal enterocytes.

Authors:  M W Smith; S Lloyd; P S James
Journal:  Q J Exp Physiol       Date:  1988-09

10.  Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial.

Authors:  Dennis A Savaiano; Andrew J Ritter; Todd R Klaenhammer; Gareth M James; Amy T Longcore; Justin R Chandler; W Allan Walker; Howard L Foyt
Journal:  Nutr J       Date:  2013-12-13       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.